-
1
-
-
0027468594
-
Somatic deletion of the neurofibromatosis type 1 gene in a neurofibrosarcoma supports a tumour suppressor gene hypothesis
-
Legius E, Marchuk DA, Collins FS, Glover TW. Somatic deletion of the neurofibromatosis type 1 gene in a neurofibrosarcoma supports a tumour suppressor gene hypothesis. Nat Genet 1993; 3: 122-126.
-
(1993)
Nat Genet
, vol.3
, pp. 122-126
-
-
Legius, E.1
Marchuk, D.A.2
Collins, F.S.3
Glover, T.W.4
-
2
-
-
65349086151
-
Mechanisms in the pathogenesis of malignant tumours in neurofibromatosis type 1
-
Brems H, Beert E, De Ravel T, Legius E. Mechanisms in the pathogenesis of malignant tumours in neurofibromatosis type 1. Lancet Oncol 2009; 10: 508-515.
-
(2009)
Lancet Oncol
, vol.10
, pp. 508-515
-
-
Brems, H.1
Beert, E.2
De Ravel, T.3
Legius, E.4
-
3
-
-
84866894408
-
Comprehensive genomic characterization of squamous cell lung cancers
-
Cancer Genome Atlas Research N. Comprehensive genomic characterization of squamous cell lung cancers. Nature 2012; 489: 519-525.
-
(2012)
Nature
, vol.489
, pp. 519-525
-
-
-
4
-
-
54549094903
-
Somatic mutations affect key pathways in lung adenocarcinoma
-
Ding L, Getz G, Wheeler DA, Mardis ER, McLellan MD, Cibulskis K et al. Somatic mutations affect key pathways in lung adenocarcinoma. Nature 2008; 455: 1069-1075.
-
(2008)
Nature
, vol.455
, pp. 1069-1075
-
-
Ding, L.1
Getz, G.2
Wheeler, D.A.3
Mardis, E.R.4
McLellan, M.D.5
Cibulskis, K.6
-
5
-
-
77955038485
-
NF1 is a tumor suppressor in neuroblastoma that determines retinoic acid response and disease outcome
-
Holzel M, Huang S, Koster J, Ora I, Lakeman A, Caron H et al. NF1 is a tumor suppressor in neuroblastoma that determines retinoic acid response and disease outcome. Cell 2010; 142: 218-229.
-
(2010)
Cell
, vol.142
, pp. 218-229
-
-
Holzel, M.1
Huang, S.2
Koster, J.3
Ora, I.4
Lakeman, A.5
Caron, H.6
-
6
-
-
73649123907
-
Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1
-
Verhaak RG, Hoadley KA, Purdom E, Wang V, Qi Y, Wilkerson MD et al. Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1. Cancer cell 2010; 17: 98-110.
-
(2010)
Cancer Cell
, vol.17
, pp. 98-110
-
-
Verhaak, R.G.1
Hoadley, K.A.2
Purdom, E.3
Wang, V.4
Qi, Y.5
Wilkerson, M.D.6
-
7
-
-
84876037369
-
Elucidating distinct roles for NF1 in melanomagenesis
-
Maertens O, Johnson B, Hollstein P, Frederick DT, Cooper ZA, Messiaen L et al. Elucidating distinct roles for NF1 in melanomagenesis. Cancer Discov 2013; 3: 338-349.
-
(2013)
Cancer Discov
, vol.3
, pp. 338-349
-
-
Maertens, O.1
Johnson, B.2
Hollstein, P.3
Frederick, D.T.4
Cooper, Z.A.5
Messiaen, L.6
-
8
-
-
84875717480
-
A genome-scale RNA interference screen implicates NF1 loss in resistance to RAF inhibition
-
Whittaker SR, Theurillat JP, Van Allen E, Wagle N, Hsiao J, Cowley GS et al. A genome-scale RNA interference screen implicates NF1 loss in resistance to RAF inhibition. Cancer Discov 2013; 3: 350-362.
-
(2013)
Cancer Discov
, vol.3
, pp. 350-362
-
-
Whittaker, S.R.1
Theurillat, J.P.2
Van Allen, E.3
Wagle, N.4
Hsiao, J.5
Cowley, G.S.6
-
9
-
-
0347725620
-
Hyperactivation of protein kinase B and ERK have discrete effects on survival, proliferation, and cytokine expression in Nf1-deficient myeloid cells
-
Donovan S, See W, Bonifas J, Stokoe D, Shannon KM. Hyperactivation of protein kinase B and ERK have discrete effects on survival, proliferation, and cytokine expression in Nf1-deficient myeloid cells. Cancer cell 2002; 2: 507-514.
-
(2002)
Cancer Cell
, vol.2
, pp. 507-514
-
-
Donovan, S.1
See, W.2
Bonifas, J.3
Stokoe, D.4
Shannon, K.M.5
-
10
-
-
0026521070
-
Aberrant regulation of ras proteins in malignant tumour cells from type 1 neurofibromatosis patients
-
Basu TN, Gutmann DH, Fletcher JA, Glover TW, Collins FS, Downward J. Aberrant regulation of ras proteins in malignant tumour cells from type 1 neurofibromatosis patients. Nature 1992; 356: 713-715.
-
(1992)
Nature
, vol.356
, pp. 713-715
-
-
Basu, T.N.1
Gutmann, D.H.2
Fletcher, J.A.3
Glover, T.W.4
Collins, F.S.5
Downward, J.6
-
11
-
-
0026528368
-
Abnormal regulation of mammalian p21ras contributes to malignant tumor growth in von Recklinghausen (type 1) neurofibromatosis
-
DeClue JE, Papageorge AG, Fletcher JA, Diehl SR, Ratner N, Vass WC et al. Abnormal regulation of mammalian p21ras contributes to malignant tumor growth in von Recklinghausen (type 1) neurofibromatosis. Cell 1992; 69: 265-273.
-
(1992)
Cell
, vol.69
, pp. 265-273
-
-
Declue, J.E.1
Papageorge, A.G.2
Fletcher, J.A.3
Diehl, S.R.4
Ratner, N.5
Vass, W.C.6
-
12
-
-
44449093081
-
TORC1 is essential for NF1-associated malignancies
-
Johannessen CM, Johnson BW, Williams SM, Chan AW, Reczek EE, Lynch RC et al. TORC1 is essential for NF1-associated malignancies. Curr Biol 2008; 18: 56-62.
-
(2008)
Curr Biol
, vol.18
, pp. 56-62
-
-
Johannessen, C.M.1
Johnson, B.W.2
Williams, S.M.3
Chan, A.W.4
Reczek, E.E.5
Lynch, R.C.6
-
13
-
-
84873809147
-
MEK inhibition exhibits efficacy in human and mouse neurofibromatosis tumors
-
Jessen WJ, Miller SJ, Jousma E, Wu J, Rizvi TA, Brundage ME et al. MEK inhibition exhibits efficacy in human and mouse neurofibromatosis tumors. J Clin Invest 2013; 123: 340-347.
-
(2013)
J Clin Invest
, vol.123
, pp. 340-347
-
-
Jessen, W.J.1
Miller, S.J.2
Jousma, E.3
Wu, J.4
Rizvi, T.A.5
Brundage, M.E.6
-
14
-
-
49849084685
-
Effective in vivo targeting of the mammalian target of rapamycin pathway in malignant peripheral nerve sheath tumors
-
Johansson G, Mahller YY, Collins MH, Kim MO, Nobukuni T, Perentesis J et al. Effective in vivo targeting of the mammalian target of rapamycin pathway in malignant peripheral nerve sheath tumors. Mol Cancer Ther 2008; 7: 1237-1245.
-
(2008)
Mol Cancer Ther
, vol.7
, pp. 1237-1245
-
-
Johansson, G.1
Mahller, Y.Y.2
Collins, M.H.3
Kim, M.O.4
Nobukuni, T.5
Perentesis, J.6
-
15
-
-
80052557069
-
Exploiting cancer cell vulnerabilities to develop a combination therapy for ras-driven tumors
-
De Raedt T, Walton Z, Yecies JL, Li D, Chen Y, Malone CF et al. Exploiting cancer cell vulnerabilities to develop a combination therapy for ras-driven tumors. Cancer cell 2011; 20: 400-413.
-
(2011)
Cancer Cell
, vol.20
, pp. 400-413
-
-
De Raedt, T.1
Walton, Z.2
Yecies, J.L.3
Li, D.4
Chen, Y.5
Malone, C.F.6
-
16
-
-
74949090309
-
The therapeutic promise of the cancer stem cell concept
-
Frank NY, Schatton T, Frank MH. The therapeutic promise of the cancer stem cell concept. J Clin Invest 2010; 120: 41-50.
-
(2010)
J Clin Invest
, vol.120
, pp. 41-50
-
-
Frank, N.Y.1
Schatton, T.2
Frank, M.H.3
-
17
-
-
0345059767
-
Applying the principles of stem-cell biology to cancer
-
Pardal R, Clarke MF, Morrison SJ. Applying the principles of stem-cell biology to cancer. Nat Rev Cancer 2003; 3: 895-902.
-
(2003)
Nat Rev Cancer
, vol.3
, pp. 895-902
-
-
Pardal, R.1
Clarke, M.F.2
Morrison, S.J.3
-
18
-
-
84857028067
-
Tumorigenic cells are common in mouse MPNSTs but their frequency depends upon tumor genotype and assay conditions
-
Buchstaller J, McKeever PE, Morrison SJ. Tumorigenic cells are common in mouse MPNSTs but their frequency depends upon tumor genotype and assay conditions. Cancer cell 2012; 21: 240-252.
-
(2012)
Cancer Cell
, vol.21
, pp. 240-252
-
-
Buchstaller, J.1
McKeever, P.E.2
Morrison, S.J.3
-
19
-
-
56749175521
-
Nf1 mutation expands an EGFR-dependent peripheral nerve progenitor that confers neurofibroma tumorigenic potential
-
Williams JP, Wu J, Johansson G, Rizvi TA, Miller SC, Geiger H et al. Nf1 mutation expands an EGFR-dependent peripheral nerve progenitor that confers neurofibroma tumorigenic potential. Cell stem cell 2008; 3: 658-669.
-
(2008)
Cell Stem Cell
, vol.3
, pp. 658-669
-
-
Williams, J.P.1
Wu, J.2
Johansson, G.3
Rizvi, T.A.4
Miller, S.C.5
Geiger, H.6
-
20
-
-
84863593847
-
PTEN and NF1 inactivation in Schwann cells produces a severe phenotype in the peripheral nervous system that promotes the development and malignant progression of peripheral nerve sheath tumors
-
Keng VW, Rahrmann EP, Watson AL, Tschida BR, Moertel CL, Jessen WJ et al. PTEN and NF1 inactivation in Schwann cells produces a severe phenotype in the peripheral nervous system that promotes the development and malignant progression of peripheral nerve sheath tumors. Cancer Res 2012; 72: 3405-3413.
-
(2012)
Cancer Res
, vol.72
, pp. 3405-3413
-
-
Keng, V.W.1
Rahrmann, E.P.2
Watson, A.L.3
Tschida, B.R.4
Moertel, C.L.5
Jessen, W.J.6
-
21
-
-
84891940023
-
EGFR-STAT3 signaling promotes formation of malignant peripheral nerve sheath tumors
-
Wu J, Patmore DM, Jousma E, Eaves DW, Breving K, Patel AV et al. EGFR-STAT3 signaling promotes formation of malignant peripheral nerve sheath tumors. Oncogene 2013; 33: 173-180.
-
(2013)
Oncogene
, vol.33
, pp. 173-180
-
-
Wu, J.1
Patmore, D.M.2
Jousma, E.3
Eaves, D.W.4
Breving, K.5
Patel, A.V.6
-
22
-
-
78649284957
-
Neoplasms with schwannian differentiation express transcription factors known to regulate normal schwann cell development
-
Pytel P, Karrison T, Can G, Tonsgard JH, Krausz T, Montag AG. Neoplasms with schwannian differentiation express transcription factors known to regulate normal schwann cell development. Int J Surg Pathol 2010; 18: 449-457.
-
(2010)
Int J Surg Pathol
, vol.18
, pp. 449-457
-
-
Pytel, P.1
Karrison, T.2
Can, G.3
Tonsgard, J.H.4
Krausz, T.5
Montag, A.G.6
-
23
-
-
0032786494
-
Mouse tumor model for neurofibromatosis type 1
-
Vogel KS, Klesse LJ, Velasco-Miguel S, Meyers K, Rushing EJ, Parada LF. Mouse tumor model for neurofibromatosis type 1. Science 1999; 286: 2176-2179.
-
(1999)
Science
, vol.286
, pp. 2176-2179
-
-
Vogel, K.S.1
Klesse, L.J.2
Velasco-Miguel, S.3
Meyers, K.4
Rushing, E.J.5
Parada, L.F.6
-
24
-
-
75449103584
-
Integrative genomic analyses of neurofibromatosis tumours identify SOX9 as a biomarker and survival gene
-
Miller SJ, Jessen WJ, Mehta T, Hardiman A, Sites E, Kaiser S et al. Integrative genomic analyses of neurofibromatosis tumours identify SOX9 as a biomarker and survival gene. EMBO molecular medicine 2009; 1: 236-248.
-
(2009)
EMBO Molecular Medicine
, vol.1
, pp. 236-248
-
-
Miller, S.J.1
Jessen, W.J.2
Mehta, T.3
Hardiman, A.4
Sites, E.5
Kaiser, S.6
-
25
-
-
0346121540
-
Neural crest development is regulated by the transcription factor Sox9
-
Cheung M, Briscoe J. Neural crest development is regulated by the transcription factor Sox9. Development 2003; 130: 5681-5693.
-
(2003)
Development
, vol.130
, pp. 5681-5693
-
-
Cheung, M.1
Briscoe, J.2
-
27
-
-
84858333682
-
The transcription factor c-Maf controls touch receptor development and function
-
Wende H, Lechner SG, Cheret C, Bourane S, Kolanczyk ME, Pattyn A et al. The transcription factor c-Maf controls touch receptor development and function. Science 2012; 335: 1373-1376.
-
(2012)
Science
, vol.335
, pp. 1373-1376
-
-
Wende, H.1
Lechner, S.G.2
Cheret, C.3
Bourane, S.4
Kolanczyk, M.E.5
Pattyn, A.6
-
28
-
-
0028154038
-
Maf and Nrl can bind to AP-1 sites and form heterodimers with Fos and Jun
-
Kerppola TK, Curran T. Maf and Nrl can bind to AP-1 sites and form heterodimers with Fos and Jun. Oncogene 1994; 9: 675-684.
-
(1994)
Oncogene
, vol.9
, pp. 675-684
-
-
Kerppola, T.K.1
Curran, T.2
-
29
-
-
0037184963
-
A new long form of c-Maf cooperates with Sox9 to activate the type II collagen gene
-
Huang W, Lu N, Eberspaecher H, De Crombrugghe B. A new long form of c-Maf cooperates with Sox9 to activate the type II collagen gene. J Biol Chem 2002; 277: 50668-50675.
-
(2002)
J Biol Chem
, vol.277
, pp. 50668-50675
-
-
Huang, W.1
Lu, N.2
Eberspaecher, H.3
De Crombrugghe, B.4
-
30
-
-
33644761738
-
Cell context reveals a dual role for Maf in oncogenesis
-
Pouponnot C, Sii-Felice K, Hmitou I, Rocques N, Lecoin L, Druillennec S et al. Cell context reveals a dual role for Maf in oncogenesis. Oncogene 2006; 25: 1299-1310.
-
(2006)
Oncogene
, vol.25
, pp. 1299-1310
-
-
Pouponnot, C.1
Sii-Felice, K.2
Hmitou, I.3
Rocques, N.4
Lecoin, L.5
Druillennec, S.6
-
31
-
-
67349241955
-
DEPTOR is an mTOR inhibitor frequently overexpressed in multiple myeloma cells and required for their survival
-
Peterson TR, Laplante M, Thoreen CC, Sancak Y, Kang SA, Kuehl WM et al. DEPTOR is an mTOR inhibitor frequently overexpressed in multiple myeloma cells and required for their survival. Cell 2009; 137: 873-886.
-
(2009)
Cell
, vol.137
, pp. 873-886
-
-
Peterson, T.R.1
Laplante, M.2
Thoreen, C.C.3
Sancak, Y.4
Kang, S.A.5
Kuehl, W.M.6
-
32
-
-
84861697039
-
An evolving role for DEPTOR in tumor development and progression
-
Wang Z, Zhong J, Inuzuka H, Gao D, Shaik S, Sarkar FH et al. An evolving role for DEPTOR in tumor development and progression. Neoplasia 2012; 14: 368-375.
-
(2012)
Neoplasia
, vol.14
, pp. 368-375
-
-
Wang, Z.1
Zhong, J.2
Inuzuka, H.3
Gao, D.4
Shaik, S.5
Sarkar, F.H.6
-
33
-
-
75149150217
-
Inhibition of Eyes Absent Homolog 4 expression induces malignant peripheral nerve sheath tumor necrosis
-
Miller SJ, Lan ZD, Hardiman A, Wu J, Kordich JJ, Patmore DM et al. Inhibition of Eyes Absent Homolog 4 expression induces malignant peripheral nerve sheath tumor necrosis. Oncogene 2010; 29: 368-379.
-
(2010)
Oncogene
, vol.29
, pp. 368-379
-
-
Miller, S.J.1
Lan, Z.D.2
Hardiman, A.3
Wu, J.4
Kordich, J.J.5
Patmore, D.M.6
-
34
-
-
0029032249
-
The regulation of AP-1 activity by mitogen-activated protein kinases
-
Karin M. The regulation of AP-1 activity by mitogen-activated protein kinases. J Biol Chem 1995; 270: 16483-16486.
-
(1995)
J Biol Chem
, vol.270
, pp. 16483-16486
-
-
Karin, M.1
-
35
-
-
78449304547
-
The role of neurofibromin in N-Ras mediated AP-1 regulation in malignant peripheral nerve sheath tumors
-
Kraniak JM, Sun D, Mattingly RR, Reiners Jr JJ, Tainsky MA. The role of neurofibromin in N-Ras mediated AP-1 regulation in malignant peripheral nerve sheath tumors. Mol Cell Biochem 2010; 344: 267-276.
-
(2010)
Mol Cell Biochem
, vol.344
, pp. 267-276
-
-
Kraniak, J.M.1
Sun, D.2
Mattingly, R.R.3
Reiners, J.J.4
Tainsky, M.A.5
-
36
-
-
0030802419
-
A dominant negative to activation protein-1 (AP1) that abolishes DNA binding and inhibits oncogenesis
-
Olive M, Krylov D, Echlin DR, Gardner K, Taparowsky E, Vinson C. A dominant negative to activation protein-1 (AP1) that abolishes DNA binding and inhibits oncogenesis. J Biol Chem 1997; 272: 18586-18594.
-
(1997)
J Biol Chem
, vol.272
, pp. 18586-18594
-
-
Olive, M.1
Krylov, D.2
Echlin, D.R.3
Gardner, K.4
Taparowsky, E.5
Vinson, C.6
-
37
-
-
0035823540
-
Induction of cellular antioxidative stress genes through heterodimeric transcription factor Nrf2/small Maf by antirheumatic gold(I) compounds
-
Kataoka K, Handa H, Nishizawa M. Induction of cellular antioxidative stress genes through heterodimeric transcription factor Nrf2/small Maf by antirheumatic gold(I) compounds. J Biol Chem 2001; 276: 34074-34081.
-
(2001)
J Biol Chem
, vol.276
, pp. 34074-34081
-
-
Kataoka, K.1
Handa, H.2
Nishizawa, M.3
-
38
-
-
0030604714
-
The proto-oncogene c-maf is responsible for tissue-specific expression of interleukin-4
-
Ho IC, Hodge MR, Rooney JW, Glimcher LH. The proto-oncogene c-maf is responsible for tissue-specific expression of interleukin-4. Cell 1996; 85: 973-983.
-
(1996)
Cell
, vol.85
, pp. 973-983
-
-
Ho, I.C.1
Hodge, M.R.2
Rooney, J.W.3
Glimcher, L.H.4
-
39
-
-
79958026380
-
The Ras-ERK and PI3K-mTOR pathways: Cross-talk and compensation
-
Mendoza MC, Er EE, Blenis J. The Ras-ERK and PI3K-mTOR pathways: Cross-talk and compensation. Trends Biochem Sci 2011; 36: 320-328.
-
(2011)
Trends Biochem Sci
, vol.36
, pp. 320-328
-
-
Mendoza, M.C.1
Er, E.E.2
Blenis, J.3
-
40
-
-
79952123613
-
A mechanistic rationale for MEK inhibitor therapy in myeloma based on blockade of MAF oncogene expression
-
Annunziata CM, Hernandez L, Davis RE, Zingone A, Lamy L, Lam LT et al. A mechanistic rationale for MEK inhibitor therapy in myeloma based on blockade of MAF oncogene expression. Blood 2011; 117: 2396-2404.
-
(2011)
Blood
, vol.117
, pp. 2396-2404
-
-
Annunziata, C.M.1
Hernandez, L.2
Davis, R.E.3
Zingone, A.4
Lamy, L.5
Lam, L.T.6
-
41
-
-
84879300153
-
RAS/MEK-Independent Gene Expression Reveals BMP2-Related Malignant Phenotypes in the Nf1-Deficient MPNST
-
Sun D, Haddad R, Kraniak JM, Horne SD, Tainsky MA. RAS/MEK-Independent Gene Expression Reveals BMP2-Related Malignant Phenotypes in the Nf1-Deficient MPNST. Mol Cancer Res 2013; 11: 616-627.
-
(2013)
Mol Cancer Res
, vol.11
, pp. 616-627
-
-
Sun, D.1
Haddad, R.2
Kraniak, J.M.3
Horne, S.D.4
Tainsky, M.A.5
-
42
-
-
2442707675
-
Integration of high-resolution array comparative genomic hybridization analysis of chromosome 16q with expression array data refines common regions of loss at 16q23-qter and identifies underlying candidate tumor suppressor genes in prostate cancer
-
Watson JE, Doggett NA, Albertson DG, Andaya A, Chinnaiyan A, Van Dekken H et al. Integration of high-resolution array comparative genomic hybridization analysis of chromosome 16q with expression array data refines common regions of loss at 16q23-qter and identifies underlying candidate tumor suppressor genes in prostate cancer. Oncogene 2004; 23: 3487-3494.
-
(2004)
Oncogene
, vol.23
, pp. 3487-3494
-
-
Watson, J.E.1
Doggett, N.A.2
Albertson, D.G.3
Andaya, A.4
Chinnaiyan, A.5
Van Dekken, H.6
-
43
-
-
84872546604
-
Prognostic significance of AKT/mTOR and MAPK pathways and antitumor effect of mTOR inhibitor in NF1-related and sporadic malignant peripheral nerve sheath tumors
-
Endo M, Yamamoto H, Setsu N, Kohashi K, Takahashi Y, Ishii T et al. Prognostic significance of AKT/mTOR and MAPK pathways and antitumor effect of mTOR inhibitor in NF1-related and sporadic malignant peripheral nerve sheath tumors. Clin Cancer Res 2013; 19: 450-461.
-
(2013)
Clin Cancer Res
, vol.19
, pp. 450-461
-
-
Endo, M.1
Yamamoto, H.2
Setsu, N.3
Kohashi, K.4
Takahashi, Y.5
Ishii, T.6
-
44
-
-
0033799930
-
Loss of neurofibromin is associated with activation of RAS/MAPK and PI3-K/AKT signaling in a neurofibromatosis 1 astrocytoma
-
Lau N, Feldkamp MM, Roncari L, Loehr AH, Shannon P, Gutmann DH et al. Loss of neurofibromin is associated with activation of RAS/MAPK and PI3-K/AKT signaling in a neurofibromatosis 1 astrocytoma. J Neuropathol Exp Neurol 2000; 59: 759-767.
-
(2000)
J Neuropathol Exp Neurol
, vol.59
, pp. 759-767
-
-
Lau, N.1
Feldkamp, M.M.2
Roncari, L.3
Loehr, A.H.4
Shannon, P.5
Gutmann, D.H.6
-
45
-
-
66849131261
-
Dual targeting of AKT and mammalian target of rapamycin: A potential therapeutic approach for malignant peripheral nerve sheath tumor
-
Zou CY, Smith KD, Zhu QS, Liu J, McCutcheon IE, Slopis JM et al. Dual targeting of AKT and mammalian target of rapamycin: A potential therapeutic approach for malignant peripheral nerve sheath tumor. Mol Cancer Ther 2009; 8: 1157-1168.
-
(2009)
Mol Cancer Ther
, vol.8
, pp. 1157-1168
-
-
Zou, C.Y.1
Smith, K.D.2
Zhu, Q.S.3
Liu, J.4
McCutcheon, I.E.5
Slopis, J.M.6
-
46
-
-
81855167585
-
DEPTOR an mTOR inhibitor, is a physiological substrate of SCF(betaTrCP) E3 ubiquitin ligase and regulates survival and autophagy
-
Zhao Y, Xiong X, Sun Y. DEPTOR an mTOR inhibitor, is a physiological substrate of SCF(betaTrCP) E3 ubiquitin ligase and regulates survival and autophagy. Mol Cell 2011; 44: 304-316.
-
(2011)
Mol Cell
, vol.44
, pp. 304-316
-
-
Zhao, Y.1
Xiong, X.2
Sun, Y.3
-
47
-
-
51349164790
-
Inhibition of mTORC1 leads to MAPK pathway activation through a PI3K-dependent feedback loop in human cancer
-
Carracedo A, Ma L, Teruya-Feldstein J, Rojo F, Salmena L, Alimonti A et al. Inhibition of mTORC1 leads to MAPK pathway activation through a PI3K-dependent feedback loop in human cancer. J Clin Invest 2008; 118: 3065-3074.
-
(2008)
J Clin Invest
, vol.118
, pp. 3065-3074
-
-
Carracedo, A.1
Ma, L.2
Teruya-Feldstein, J.3
Rojo, F.4
Salmena, L.5
Alimonti, A.6
-
48
-
-
33644974752
-
Nfl gene inactivation in acute myeloid leukemia cells confers cytarabine resistance through MAPK and mTOR pathways
-
Yin B, Morgan K, Hasz DE, Mao Z, Largaespada DA. Nfl gene inactivation in acute myeloid leukemia cells confers cytarabine resistance through MAPK and mTOR pathways. Leukemia 2006; 20: 151-154.
-
(2006)
Leukemia
, vol.20
, pp. 151-154
-
-
Yin, B.1
Morgan, K.2
De, H.3
Mao, Z.4
Largaespada, D.A.5
-
49
-
-
84863643200
-
A shared molecular mechanism underlies the human rasopathies Legius syndrome and Neurofibromatosis-1
-
Stowe IB, Mercado EL, Stowe TR, Bell EL, Oses-Prieto JA, Hernandez H et al. A shared molecular mechanism underlies the human rasopathies Legius syndrome and Neurofibromatosis-1. Genes Dev 2012; 26: 1421-1426.
-
(2012)
Genes Dev
, vol.26
, pp. 1421-1426
-
-
Stowe, I.B.1
Mercado, E.L.2
Stowe, T.R.3
Bell, E.L.4
Oses-Prieto, J.A.5
Hernandez, H.6
|